Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | BCL6 | P41182 | 17/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31521004 | 0.95 | CYP1A2 (0.53) | CYP1A2BCL6PKM | |
| SCHEMBL31520620 | 0.93 | CYP1A2 (0.49) | CYP1A2BCL6PKMNCOR2 | |
| SCHEMBL23357569 | 0.92 | CYP1A2 (0.63) | CYP1A2BCL6PKM | |
| SCHEMBL20570547 | 0.89 | CYP1A2 (0.53) | CYP1A2BCL6PKM | |
| SCHEMBL31520705 | 0.88 | CYP1A2 (0.58) | CYP1A2BCL6PKM | |
| SCHEMBL23357615 | 0.86 | CYP1A2 (0.50) | CYP1A2BCL6PKM | |
| SCHEMBL20568808 | 0.83 | CYP1A2 (0.47) | CYP1A2BCL6PKM | |
| SCHEMBL29203262 | 0.83 | CYP1A2 (0.53) | CYP1A2BCL6PKM | |
| SCHEMBL29203264 | 0.83 | CYP1A2 (0.53) | CYP1A2BCL6PKM | |
| SCHEMBL30232265 | 0.83 | CYP1A2 (0.53) | CYP1A2BCL6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4061834-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-28 | — | — | EP | claimed |
| US-20220281931-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-08 | — | — | US | claimed |
| WO-2021102283-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-27 | — | — | WO | claimed |
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
| CN-118561812-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-4380919-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4374858-A2 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-3630291-B9 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| CN-111163839-B | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3630291-B1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023015164-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4061834-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| US-20220281931-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2021102283-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| CN-111163839-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-3630291-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215801-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | CYP1A2 2414/4885BCL6 1/4885PKM 1756/4885 |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | CYP1A2 2414/4885BCL6 1/4885PKM 1756/4885 |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | CYP1A2 2414/4885BCL6 1/4885PKM 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.